FDA clears way for Mayo Clinic to accelerate production of stem cells for clinical trials through automation

Jan 10, 2018 | Mayo Clinic Chest Surgery Team | @mayoclinicchestsurgeryteam | Comments (1)

Steam Cell Automation

Mayo Clinic News Network

JACKSONVILLE, Fla. — The U.S. Food and Drug Administration (FDA) has agreed to allow Mayo Clinic to use an automated bioreactor-based stem cell production platform on its campus in Jacksonville, Florida. This enables the Mayo Clinic Center for Regenerative Medicine to produce cells from the bone marrow of a stem cell donor in quantities large enough to make several doses that can be used as treatments in clinical trials.

Continue reading the full article atMayo Clinic News Network 

Helpful links


Interested in more newsfeed posts like this? Go to the Chest Surgery blog.

Hello @mayoclinicchestsurgeryteam, This is great news for many who have hopes of one day being able to receive stem cell treatment in hope of one day providing a healing process for incurable diseases. Thanks Mayo Clinic!!!!

Please sign in or register to post a reply.